Immuneering (IMRX) Total Current Liabilities (2020 - 2024)
Historic Total Current Liabilities for Immuneering (IMRX) over the last 5 years, with Q3 2024 value amounting to $6.9 million.
- Immuneering's Total Current Liabilities rose 2308.11% to $6.9 million in Q3 2024 from the same period last year, while for Sep 2024 it was $6.9 million, marking a year-over-year increase of 2308.11%. This contributed to the annual value of $7.8 million for FY2023, which is 258.96% down from last year.
- Immuneering's Total Current Liabilities amounted to $6.9 million in Q3 2024, which was up 2308.11% from $6.8 million recorded in Q2 2024.
- Immuneering's 5-year Total Current Liabilities high stood at $8.1 million for Q4 2022, and its period low was $2.3 million during Q4 2020.
- For the 5-year period, Immuneering's Total Current Liabilities averaged around $5.6 million, with its median value being $5.5 million (2023).
- Its Total Current Liabilities has fluctuated over the past 5 years, first soared by 14974.28% in 2021, then plummeted by 2251.3% in 2023.
- Over the past 5 years, Immuneering's Total Current Liabilities (Quarter) stood at $2.3 million in 2020, then surged by 149.74% to $5.6 million in 2021, then soared by 42.96% to $8.1 million in 2022, then dropped by 2.59% to $7.8 million in 2023, then decreased by 11.8% to $6.9 million in 2024.
- Its last three reported values are $6.9 million in Q3 2024, $6.8 million for Q2 2024, and $5.2 million during Q1 2024.